The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
Primary Purpose
IBS
Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Probiotics
Placebo
Sponsored by
About this trial
This is an interventional basic science trial for IBS
Eligibility Criteria
Inclusion Criteria:
- Signed informed consent
- Fulfilled Rome IV diagnostic criteria for IBS with predominant diarrhoea
- Mild-to-severe IBS symptoms according to the IBS severity scoring system (IBS-SSS; a score of ≥75)
- Age: 18-65 years
Exclusion Criteria:
- Known organic gastrointestinal disease (e.g. inflammatory bowel disease, IBD)
- Previous abdominal surgery which might influence gastrointestinal function, except appendectomy and cholecystectomy
- History of or present gastrointestinal malignancy or polyposis
- Recently (within the last 6 months) diagnosed gastrointestinal infection
- Current diagnosis of dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
- Chronic neurological/neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis)
- Autoimmune disease and/or patients receiving immunosuppressive medications
- Chronic pain syndromes (e.g. fibromyalgia)
- Chronic fatigue syndrome
- Severe endometriosis
- Coeliac disease
- Recently (within the last 3 months) diagnosed lactose intolerance
- Females who are pregnant or breast-feeding
- Regular intake of systemic corticosteroids and anti-inflammatory medication (including non-steroidal anti-inflammatory drugs, NSAIDs) during the last 3 months or incidental use in the last 2 weeks prior to randomisation
- Recent (< 4 weeks) intake of proton pump inhibitors, PPIs (e.g., omeprazol)
- Use of anti-depressants in the last 3 months
- Regular oral intake of mast cell stabilising drugs (e.g. sodium cromoglycate) during the last 3 months or incidental use in the last 2 weeks prior to screening
- Antimicrobial treatment 6 weeks prior to first screening visit
- Antimicrobial prophylaxis (eg. acne, urinary tract infection)
- Regular consumption of probiotic products 4 weeks prior to first baseline visit
- Concurrent or recent (<4 weeks) use of nutritional supplements or herb products affecting intestinal function (e.g. aloe vera, St. John´s Wort, fibres, prebiotics) if the investigator considers those could affect the study outcome.
- Inability to maintain exercise routine and dietary pattern during the study.
- Abuse of alcohol or drugs
- Any clinically significant present or past disease/condition which in the investigator's opinion could interfere with the results of the trial
Sites / Locations
- Örebro University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Lactobacillus reuteri strain 1
Lactobacillus reuteri strain 2
Placebo
Arm Description
Probiotic compound
Probiotic compound
Placebo
Outcomes
Primary Outcome Measures
Change in small intestinal permeability after 6 weeks (urinary lactulose/rhamnose ratio, 0-5h)
Difference in small intestinal permeability, measured as the urinary lactulose/rhamnose secretion ratio (0-5h), after a 6-week intervention with the probiotic products compared to the placebo product
Secondary Outcome Measures
Change in small intestinal permeability after 3 weeks (urinary lactulose/rhamnose ratio, 0-5h)
Difference in small intestinal permeability, measured as the urinary lactulose/rhamnose secretion ratio (0-5h), after a 3-week intervention with the probiotic products compared to the placebo product
Change in whole gut permeability after 6 weeks (urinary sucralose/erythritol ratio, 0-24h)
Difference between intervention with the probiotic products compared to the placebo in whole gut permeability, measured as urinary sucralose/erythritol excretion ratio (0-24hrs)
Change in whole gut permeability after 3 weeks (urinary sucralose/erythritol excretion ratio, 0-24h)
Difference between intervention with the probiotic products compared to the placebo in whole gut permeability, measured as urinary sucralose/erythritol excretion ratio (0-24hrs)
Change in colonic permeability after 6 weeks (urinary sucralose/erythritol ratio, 5-24h)
Difference between intervention with the probiotic products compared to the placebo in colonic permeability, measured as urinary sucralose/erythritol ratio (5-24hrs)
Change in colonic permeability after 3 weeks (urinary sucralose/erythritol ratio, 5-24hrs)
Difference between intervention with the probiotic products compared to the placebo in colonic permeability, measured as urinary sucralose/erythritol ratio (5-24hrs)
Change in gastroduodenal permeability after 6 weeks (urinary sucrose excretion, 0-5hrs)
Difference between intervention with the probiotic products compared to the placebo in gastroduodenal permeability, measured as urinary sucrose excretion (0-5hrs)
Change in gastroduodenal permeability after 3 weeks (urinary sucrose excretion, 0-5hrs)
Difference between intervention with the probiotic products compared to the placebo in gastroduodenal permeability, measured as urinary sucrose excretion (0-5hrs)
Change in inflammatory status after 3 weeks
Difference between intervention with the probiotic products compared to the placebo in inflammatory markers in blood (e.g. high-sensitive C-reactive protein)
Change in inflammatory status after 6 weeks
Difference between intervention with the probiotic products compared to the placebo in inflammatory markers in blood (e.g. high-sensitive C-reactive protein)
Full Information
NCT ID
NCT03986476
First Posted
June 7, 2019
Last Updated
September 8, 2021
Sponsor
Örebro University, Sweden
1. Study Identification
Unique Protocol Identification Number
NCT03986476
Brief Title
The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
Official Title
The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
March 26, 2019 (Actual)
Primary Completion Date
May 10, 2021 (Actual)
Study Completion Date
May 10, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Örebro University, Sweden
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will investigate the effects of supplementation with two different probiotic products (Lactobacillus reuteri strains) on the intestinal barrier function, gut health and stress symptoms in diarrhoea-predominant irritable bowel syndrome (IBS-D) patients.
Detailed Description
After having given their written informed consent, subjects will complete screening procedures to evaluate their eligibility for the study (visit 1). Study participants will undergo two baseline visits (visits 2 and 3, 3 weeks apart) to account for individual variations, and will then be randomly assigned to 6-week intake of one of two Lactobacillus reuteri strains, or placebo in a ratio of 1:1:1 (stratified by sex). Participants will attend a study visit three weeks into the intervention (visit 4) and at the end of the intervention (visit 5, week 6). The intestinal permeability will be assessed using a standardized multi-sugar test at visit 2, visit 3, visit 4, and at end of intervention (visit 5). Blood, saliva and faecal samples will be collected at visit 2-5. In addition, gastrointestinal symptoms will be recorded at those visits (using Gastrointestinal symptom rating scale-IBS, GSRS-IBS; IBS severity scoring system, IBS- SSS). Quality of life using the 5Q-5D-5L and Hospital Anxiety and Depression Scale (HADS) scores will also be recorded at those visits. In addition, at visit 3 and visit 5, the IBS-Quality of life (IBS-QoL) and the Perceived Stress Scale (PSS) will be completed. In a daily diary, participants will record stool frequency and consistency from visit 2 until end-of-study visit 5. Dietary habits of the patients will be assessed via a food frequency questionnaire (FFQ) and a 3-day food diary before the intervention (between visit 2 and 3).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IBS
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
65 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lactobacillus reuteri strain 1
Arm Type
Experimental
Arm Description
Probiotic compound
Arm Title
Lactobacillus reuteri strain 2
Arm Type
Experimental
Arm Description
Probiotic compound
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics
Intervention Description
5x10^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
Primary Outcome Measure Information:
Title
Change in small intestinal permeability after 6 weeks (urinary lactulose/rhamnose ratio, 0-5h)
Description
Difference in small intestinal permeability, measured as the urinary lactulose/rhamnose secretion ratio (0-5h), after a 6-week intervention with the probiotic products compared to the placebo product
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Change in small intestinal permeability after 3 weeks (urinary lactulose/rhamnose ratio, 0-5h)
Description
Difference in small intestinal permeability, measured as the urinary lactulose/rhamnose secretion ratio (0-5h), after a 3-week intervention with the probiotic products compared to the placebo product
Time Frame
3 weeks
Title
Change in whole gut permeability after 6 weeks (urinary sucralose/erythritol ratio, 0-24h)
Description
Difference between intervention with the probiotic products compared to the placebo in whole gut permeability, measured as urinary sucralose/erythritol excretion ratio (0-24hrs)
Time Frame
6 weeks
Title
Change in whole gut permeability after 3 weeks (urinary sucralose/erythritol excretion ratio, 0-24h)
Description
Difference between intervention with the probiotic products compared to the placebo in whole gut permeability, measured as urinary sucralose/erythritol excretion ratio (0-24hrs)
Time Frame
3 weeks
Title
Change in colonic permeability after 6 weeks (urinary sucralose/erythritol ratio, 5-24h)
Description
Difference between intervention with the probiotic products compared to the placebo in colonic permeability, measured as urinary sucralose/erythritol ratio (5-24hrs)
Time Frame
6 weeks
Title
Change in colonic permeability after 3 weeks (urinary sucralose/erythritol ratio, 5-24hrs)
Description
Difference between intervention with the probiotic products compared to the placebo in colonic permeability, measured as urinary sucralose/erythritol ratio (5-24hrs)
Time Frame
3 weeks
Title
Change in gastroduodenal permeability after 6 weeks (urinary sucrose excretion, 0-5hrs)
Description
Difference between intervention with the probiotic products compared to the placebo in gastroduodenal permeability, measured as urinary sucrose excretion (0-5hrs)
Time Frame
6 weeks
Title
Change in gastroduodenal permeability after 3 weeks (urinary sucrose excretion, 0-5hrs)
Description
Difference between intervention with the probiotic products compared to the placebo in gastroduodenal permeability, measured as urinary sucrose excretion (0-5hrs)
Time Frame
3 weeks
Title
Change in inflammatory status after 3 weeks
Description
Difference between intervention with the probiotic products compared to the placebo in inflammatory markers in blood (e.g. high-sensitive C-reactive protein)
Time Frame
3 weeks
Title
Change in inflammatory status after 6 weeks
Description
Difference between intervention with the probiotic products compared to the placebo in inflammatory markers in blood (e.g. high-sensitive C-reactive protein)
Time Frame
6 weeks
Other Pre-specified Outcome Measures:
Title
Change in stool frequency and consistency (daily diary on bowel movement using Bristol Stool Chart)
Description
Difference between intervention with the probiotic products compared to the placebo in stool frequency and consistency
Time Frame
3 weeks
Title
Change in stool frequency and consistency (daily diary on bowel movement using Bristol Stool Chart)
Description
Difference between intervention with the probiotic products compared to the placebo in stool frequency and consistency
Time Frame
6 weeks
Title
Change in gastrointestinal symptoms measured by the IBS-specific gastrointestinal symptom rating scale (GSRS-IBS)
Description
Difference between intervention with the probiotic products compared to the placebo in gastrointestinal symptoms (GSRS-IBS total score range 0-3, 0-no symptoms, 3-extreme degree of symptoms)
Time Frame
3 weeks
Title
Change in gastrointestinal symptoms measured by the IBS symptom severity score (IBS-SSS)
Description
Difference between intervention with the probiotic products compared to the placebo in gastrointestinal symptoms (IBS-SSS, total score range 0-500, 0-no symptoms, 500-extreme degree of symptoms)
Time Frame
3 weeks
Title
Change in gastrointestinal symptoms measured by the IBS-specific gastrointestinal symptom rating scale (GSRS-IBS)
Description
Difference between intervention with the probiotic products compared to the placebo in gastrointestinal symptoms (GSRS-IBS total score range 0-3, 0-no symptoms, 3-extreme degree of symptoms)
Time Frame
6 weeks
Title
Change in gastrointestinal symptoms measured by the IBS symptom severity score (IBS-SSS)
Description
Difference between intervention with the probiotic products compared to the placebo in gastrointestinal symptoms (IBS-SSS, total score range 0-500, 0-no symptoms, 500-extreme degree of symptoms)
Time Frame
6 weeks
Title
Change in quality of life measured by IBS-specific quality of life (IBS-QOL) questionnaire
Description
Difference between intervention with the probiotic products compared to the placebo in quality of life (IBS-QOL total range, range: 0-100, 0-low quality of life, 100-high quality of life)
Time Frame
3 weeks
Title
Change in quality of life measured by IBS-specific quality of life (IBS-QOL) questionnaire
Description
Difference between intervention with the probiotic products compared to the placebo in quality of life IBS-QOL total range, range: 0-100, 0-low quality of life, 100-high quality of life)
Time Frame
6 weeks
Title
Change in perceived stress using the perceived stress scale (PSS)
Description
Difference between intervention with the probiotic products compared to the placebo in perceived stress (PSS range 0-40: 0-no stress, 40-high stress)
Time Frame
3 weeks
Title
Change in perceived stress using the perceived stress scale (PSS)
Description
Difference between intervention with the probiotic products compared to the placebo in perceived stress (PSS range 0-40: 0-no stress, 40-high stress)
Time Frame
6 weeks
Title
Change in anxiety and depression symptoms using the Hospital Anxiety and Depression Scale (HADS)
Description
Difference between intervention with the probiotic products compared to the placebo in anxiety and depression symptoms (HADS range: 0 to 21 for anxiety and 0 to 21 for depression, 0-low levels, 21 high levels)
Time Frame
3 weeks
Title
Change in anxiety and depression symptoms using the Hospital Anxiety and Depression Scale (HADS)
Description
Difference between intervention with the probiotic products compared to the placebo in anxiety and depression symptoms (HADS range: 0 to 21 for anxiety and 0 to 21 for depression, 0-low levels, 21 high levels)
Time Frame
6 weeks
Title
Change in salivary cortisol levels
Description
Difference between intervention with the probiotic products compared to the placebo in salivary cortisol levels
Time Frame
3 weeks
Title
Change in salivary cortisol levels
Description
Difference between intervention with the probiotic products compared to the placebo in salivary cortisol levels
Time Frame
6 weeks
Title
Change in intestinal microbiota composition (16S rRNA-based next generation sequencing of faecal samples) after probiotic intervention
Description
Difference between intervention with the probiotic products compared to the placebo in intestinal microbiota composition
Time Frame
3 weeks
Title
Change in intestinal microbiota composition (16S rRNA-based next generation sequencing of faecal samples) after probiotic intervention
Description
Difference between intervention with the probiotic products compared to the placebo in intestinal microbiota composition
Time Frame
6 weeks
Title
Change in metabolomic profile in faecal samples after probiotic intervention
Description
Difference between intervention with the probiotic products compared to the placebo in metabolomic profile in faecal samples
Time Frame
3 weeks
Title
Change in metabolomic profile in faecal samples after probiotic intervention
Description
Difference between intervention with the probiotic products compared to the placebo in metabolomic profile in faecal samples
Time Frame
6 weeks
Title
Change in metabolomic profile in blood samples after probiotic intervention
Description
Difference between intervention with the probiotic products compared to the placebo in metabolomic profile in faecal samples
Time Frame
3 weeks
Title
Change in metabolomic profile in blood samples after probiotic intervention
Description
Difference between intervention with the probiotic products compared to the placebo in metabolomic profile in faecal samples
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed informed consent
Fulfilled Rome IV diagnostic criteria for IBS with predominant diarrhoea
Mild-to-severe IBS symptoms according to the IBS severity scoring system (IBS-SSS; a score of ≥75)
Age: 18-65 years
Exclusion Criteria:
Known organic gastrointestinal disease (e.g. inflammatory bowel disease, IBD)
Previous abdominal surgery which might influence gastrointestinal function, except appendectomy and cholecystectomy
History of or present gastrointestinal malignancy or polyposis
Recently (within the last 6 months) diagnosed gastrointestinal infection
Current diagnosis of dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
Chronic neurological/neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis)
Autoimmune disease and/or patients receiving immunosuppressive medications
Chronic pain syndromes (e.g. fibromyalgia)
Chronic fatigue syndrome
Severe endometriosis
Coeliac disease
Recently (within the last 3 months) diagnosed lactose intolerance
Females who are pregnant or breast-feeding
Regular intake of systemic corticosteroids and anti-inflammatory medication (including non-steroidal anti-inflammatory drugs, NSAIDs) during the last 3 months or incidental use in the last 2 weeks prior to randomisation
Recent (< 4 weeks) intake of proton pump inhibitors, PPIs (e.g., omeprazol)
Use of anti-depressants in the last 3 months
Regular oral intake of mast cell stabilising drugs (e.g. sodium cromoglycate) during the last 3 months or incidental use in the last 2 weeks prior to screening
Antimicrobial treatment 6 weeks prior to first screening visit
Antimicrobial prophylaxis (eg. acne, urinary tract infection)
Regular consumption of probiotic products 4 weeks prior to first baseline visit
Concurrent or recent (<4 weeks) use of nutritional supplements or herb products affecting intestinal function (e.g. aloe vera, St. John´s Wort, fibres, prebiotics) if the investigator considers those could affect the study outcome.
Inability to maintain exercise routine and dietary pattern during the study.
Abuse of alcohol or drugs
Any clinically significant present or past disease/condition which in the investigator's opinion could interfere with the results of the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert J Brummer, MD, PhD
Organizational Affiliation
Örebro University, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Örebro University
City
Örebro
State/Province
Örebro Län
ZIP/Postal Code
70182
Country
Sweden
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
No individual participant data will be shared, only data on group level will
Learn more about this trial
The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
We'll reach out to this number within 24 hrs